$1.76
-0.065-3.56%
Ult. Agg.: Oct 23, 7:07 AM
Acrivon Therapeutics (ACRV) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.50 | $-0.51 | $-0.47 | $-0.58 |
| Actual | $-0.43 | $-0.49 | $-0.49 | $-0.47 |
| Surprise | +14.0% | +3.92% | -4.26% | +19.0% |
| Revenue | ||||
| Estimate | $464000 | $498304 | $541598 | — |
| Actual | $0 | $0 | — | $0 |
| Surprise | -100.0% | -100.0% | -100.0% | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.44 | $-0.43 | $-0.48 | $-0.51 |
| Revenue | ||||
| Consensus | $606000 | — | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.43 | $-0.50 | 14.0 % |
| Q1 | May 13, 2026 | $-0.49 | $-0.51 | 3.92 % |
| Q4 | Mar 19, 2026 | $-0.49 | $-0.47 | -4.26 % |
| Q3 | Nov 13, 2025 | $-0.47 | $-0.58 | 19.0 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $0 | $464.00K | -100.0 % |
| Q1 | May 13, 2026 | $0 | $498.30K | -100.0 % |
| Q4 | Mar 19, 2026 | $0 | $541.60K | -100.0 % |